What's breaking now, across thousands of outlets.
(MedPage Today) -- Investigational gefurulimab, a dual-binding nanobody that blocks complement component 5 (C5) activation, sustained functional improvements for 1 year in people with generalized myasthenia gravis, data from the open-label extension...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.
Sen. Chuck Grassley (R-Iowa) on Friday called on the Trump administration to finalize its proposed rule limiting the sale of kratom, a plant with opioid-like properties that can be bought over the…
FDA Chief Scientist Steven Kozlowski, MD, said the updated FARS would come out early in FY 2027 but offered no further specifics on timing.
Aviceda Therapeutics, a biotech that had planned to take an eye drug into Phase 3 this year despite a mid-stage clinical setback, is in the process of winding down, a source familiar with the decision…
Engineering for the Systemic: VR, Metabolic Health, and Visual Coordination I've always been fascinated by how hardware can solve biological constraints.
The MDC announced on April 18, 2026, through a letter with Ref. MDC/20/V1/165, that the CRE would commence in 2026, setting out examination periods, eligibility requirements and other implementation…
Details of a new injection that targets fat cells will be released at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept. 28–Oct. 2).
